AR OVEREXPRESSION

CI-VAR-00003025Explore in graph →CIViC 359

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
AR OVEREXPRESSION	Dactolisib	Predictive	D	Supports Sensitivity Response	3	accepted	EID859 In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroductio… (full text at CIViC) PMID 24356815 · Wang et al., 2014 · Open in CIViC	civic
Malignant Salivary Gland Neoplasm1
AR OVEREXPRESSION	Bicalutamide + LeuprolideCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID6953 In this single institution, open-label, single arm, phase II Trial, salivary gland carcinomas, staining positive for androgen receptor expression on IHC (minimum of 1% tumor cells), were treated with …

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.